Elanco Animal Health (ELAN) EBIT (2017 - 2026)

Elanco Animal Health has disclosed EBIT across 10 years of filings, most recently posting $307.0 million for Q1 2026.

• EBIT for Q1 2026 came in at $307.0 million, up 23.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $853.0 million (up 211.8% YoY), and the FY2025 annual result was $795.0 million, up 152.48% from the prior year.
• EBIT came in at $307.0 million for Q1 2026 at Elanco Animal Health, up from $158.0 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $307.0 million in Q1 2026 to a low of -$1.6 billion in Q3 2023.
• The 5-year median for EBIT is -$498.0 million (2022), against an average of -$324.9 million.
• Across the five-year window, EBIT slumped 206.98% in 2023 and surged 149.5% in 2025, its largest moves.
• Elanco Animal Health's EBIT stood at -$537.0 million in 2022, then slipped by 19.74% to -$643.0 million in 2023, then increased by 14.15% to -$552.0 million in 2024, then jumped by 128.62% to $158.0 million in 2025, then soared by 94.3% to $307.0 million in 2026.
• The last three EBIT figures came in at $307.0 million (Q1 2026), $158.0 million (Q4 2025), and $167.0 million (Q3 2025), per Business Quant data.